Coronary Artery
Recently Published Documents


(FIVE YEARS 33805)



2021 ◽  
Vol 150 ◽  
pp. 110635
Seyyede-Ozra Yasrebi ◽  
Sara Momtazmanesh ◽  
Hossein Sanjari Moghaddam ◽  
Nazila Shahmansouri ◽  
Maryam Mehrpooya ◽  

2021 ◽  
Vol 13 (1) ◽  
Maha Sadek El Derh ◽  
Samar Mohamed Abdel Twab ◽  
Mohamed Elgouhary

Abstract Background Off pump coronary artery revascularization (OPCAB) surgeries have benefits over the conventional on pump cardiac surgery, because it avoids the trauma caused by cardiopulmonary bypass (CPB) and minimize aortic manipulation. However, some disadvantages of OPCAB include the concern of ineffective coronary revascularization. Some drugs have shown the ability to protect the myocardium in different studies, by different methods. The usage of intralipid has been shown to make a better functional recovery of the cardiac muscles and help to decrease the myocardial infarct size, it shortens the action potential time, which show polyunsaturated fatty acids diets mechanism as an antiarrhythmic drug, and are associated with low incidence of coronary artery disease. Methods We divided patients into two groups according to the randomization envelopes: intralipid group (group A) received 1.5 ml/kg intralipid 20% through central venous line after sternotomy over 1 h and during infusion, blood pressure, heart rate, and temperature were monitored all through the infusion time. Control group (group B) received normal saline 0.9% in the same volume over the same duration. Results This study showed that infusion of 1.5 ml/kg intralipid after sternotomy in off pump coronary artery revascularization given as preconditioning agent improve the myocardial ischemia reperfusion injury, decrease the need for high doses of nor adrenaline infusion after revascularization, earlier normalization in troponin levels starting 24 h after surgery and higher values of cardiac index were measured in ICU using PICCO. Conclusions This study showed the benefits of infusion of 1.5 ml/kg of intralipid after sternotomy, in preconditioning during OPCABG. Preconditioning with intralipid proved to decrease reperfusion injury in myocardium expressed by improvement in cardiac functions (EF and cardiac index) and normalization of specific cardiac marker (cardiac troponin I).

2021 ◽  
Afek Kodesh ◽  
Eli Lev ◽  
Dorit Leshem-Lev ◽  
Alejandro Solodky ◽  
Ran Kornowski ◽  

Abstract Purpose: Calcium channel blockers (CCBs) do not reduce the risk of initial or recurrent myocardial infarction (MI) in patients diagnosed with stable coronary artery disease (CAD). The aim of this current study was to evaluate the association between CCBs and aspirin resistance in patients with CAD. Methods: Patients with stable CAD who were regularly taking aspirin (75-100 mg qd) for at least one month prior to enrollment in the study were included. The VerifyNow system was used for platelet function testing with high on-aspirin platelet reactivity (HAPR) defined as aspirin reaction units (ARU) >550. We compared patients treated with CCBs versus control group. Results: 503 patients with CAD were included in this study, 88 were treated with CCBs; Mean age (67.9±9.7 in the CCB group vs 66.5±11.4 in the control group, p=0.288), gender (77.3 male vs. 82.9%, p=0.214) and rates of diabetes mellitus (34.7 vs. 36.9%, p=.121) were similar. Rates of hypertension were higher in the CCB group (83.9 vs. 63.5%, p<0.01), but rates of past MI were lower (47.1 vs. 59.7%, p=0.039). The mean ARU was 465.4P70.0 for patients treated with CCBs versus 445.2u60.0 in controls (p=0.006). Similarly, 15.9% of CCB patients demonstrated HAPR compared to 7.0% (p=0.006). In a multivariate analysis, the administration of CCBs was independently associated with HAPR (OR- 1.72, 95% CI 1.04 – 8.91, p=0.047). Conclusions: Usage of CCBs is positively correlated with aspirin resistance. These findings may suggest an adverse pharmacologic effect of CCBs among patients with stable CAD treated with aspirin.

2021 ◽  
Vol 10 (20) ◽  
pp. 4708
Silvia Calabria ◽  
Giulia Ronconi ◽  
Letizia Dondi ◽  
Carlo Piccinni ◽  
Enrico Cinconze ◽  

Background: This study describes patients with coronary artery disease (CAD) who are eligible for secondary prevention and assesses their healthcare consumption and costs from the perspective of the Italian National Health Service (INHS). Methods: From the Fondazione Ricerca e Salute’s database, which collects Italian healthcare administrative data, all patients aged ≥ 35, with ≥1 primary in-hospital CAD diagnosis and/or procedure on the coronary arteries, or with the specific disease exemption code, and who are suitable for long-term secondary prevention treatments, were identified in 2018 and analyzed. Demographics, comorbidities, one-year supplied drugs, hospitalizations, and costs were analyzed. Results: From >3 million inhabitants aged ≥ 35, 46,063 (1.3%) were identified (72.1% males, mean age 70 ± 12; approximately 50% with ≥3 comorbidities). During a one-year follow-up, 96.4% were treated with ≥1 drug for secondary prevention (mainly antiplatelets and lipid lowering agents), 69.4% with ≥1 concomitant cardiovascular drug, and 95.8% with ≥1 concomitant non-cardiovascular therapy. Within one year, 30.6% of patients were hospitalized at least once, mostly due to non-cardiovascular events. Calculated by mean, the INHS paid EUR 6078 per patient. Conclusions: This analysis confirms the relevant burden of CAD for patients with many comorbidities and who are frequently hospitalized, and the burden on the INHS. A multidisciplinary healthcare approach is encouraged to improve patients’ outcomes and reduce costs for the INHS.

Chao Yue ◽  
Jian Yu ◽  
Jun Yan ◽  
Qiang Wang

Inha Jung ◽  
Hyemi Kwon ◽  
Se Eun Park ◽  
Kyung-Do Han ◽  
Yong-Gyu Park ◽  

Miren Vicente ◽  
Marcos García-Guimaraes ◽  
Neus Salvatella ◽  
Álvaro Aparisi ◽  
Alejandro Negrete ◽  

Fatih Bayraktar ◽  
Mehmet Bademci ◽  
Cemal Kocaaslan ◽  
Ahmet Oztekin ◽  
Ebuzer Aydın

2021 ◽  
Vol 49 (7) ◽  
pp. 556-567
Fatih Aydin ◽  
Ercan Aksit ◽  
Ozgu Turgay Yildirim ◽  
Ayse Huseyinoglu Aydin ◽  

Nidheesh Chooriyil ◽  
Thanath Krishnan Nair Jayakumar ◽  
Dhanya Sasidharan Palappallil

Background: Post-operative atrial fibrillation is a common post-operative complication and has significant morbidity and mortality. This study was done with an objective to determine the association of various medication use in patients undergoing coronary artery bypass graft (CABG) with post-operative atrial fibrillation (POAF).Methods: This was a prospective observational study done in the department of cardiovascular and thoracic surgery of GMC Kottayam from December 2019 to December 2020 after obtaining institutional review board clearance. A sample size of 334 was fixed and patients undergoing off pump (OP) CABG were consecutively recruited in the study. The association of intraoperative and postoperative medication use with occurrence of POAF were analysed using the univariate analysis with a p<0.05 using the SPSS 16 software.Results: Peri-operative inotrope use was found to be significantly associated with post operative atrial fibrillation odds ratio 1.08 (95% CI 1.02-1.13). We could not find any association with preoperative use of beta blockers/agonist, antidiabetics, levothyroxine, ACE inhibitors or antiplatelet drugs. All the patients 60 (18%) who developed POAF were given amiodarone as per protocol.Conclusions: Perioperative inotrope use was found to have significant association with the development of post operative atrial fibrillation following OPCABG. More multi-institutional studies with determination of association with individual drugs and doses with POAF need to be conducted in future.

Sign in / Sign up

Export Citation Format

Share Document